Sanofi stock holds steady as India unit boosts profit and secures tax refund

Sanofi (ISIN FR0000127771) stock closed at $43.71 on the Nasdaq on August 12, 2026, with MarketBeat data showing a modest 0.34% gain for the session as investors digested stronger second-quarter figures from Sanofi India and a newly sanctioned tax refund from Goa authorities.

Nasdaq-listed ADR trades around $43

According to MarketBeat data on the Sanofi ADR, the shares finished regular trading on August 12, 2026, at $43.71, up $0.15 on the day, a move of approximately 0.34% that left the stock in extended trading at $43.25, down 1.05% versus the close.

A separate snapshot from TradingKey indicates an end-of-session price of $43.74 for Sanofi on August 12, 2026, with a reported market capitalization of about $104.82 billion, underscoring the company’s scale in the global pharmaceuticals space.

Sanofi India reports double-digit Q2 FY26 profit growth

Beyond the ADR’s steady performance, recent coverage of Sanofi’s India subsidiary highlights a notable improvement in quarterly profitability. A news update on Scanx Trade states that Sanofi India’s profit before tax for the second quarter of fiscal 2026 rose 19% year-over-year to ?1,123 crore, marking a clear double-digit advance compared with the same period of fiscal 2025.

The same article references a shorter-term figure indicating that profit before tax in the latest reported quarter amounted to ?112 crore, again for Q2 FY26, which benchmarks the subsidiary’s operational performance at the more granular level and underscores that profits have expanded meaningfully versus the prior-year period.

For investors, the 19% year-over-year increase in profit before tax in Q2 FY26 is an important signal that Sanofi’s India business is generating growing earnings even as the wider pharmaceuticals sector faces pricing and regulatory pressures. The combination of a ?1,123 crore profit before tax on a fiscal-year-to-date basis and a ?112 crore quarterly result suggests that the subsidiary is contributing constructively to the wider group’s income base.

GST refund from Goa authorities strengthens cash position

The Scanx Trade report also notes that Sanofi India has secured a GST refund sanction totaling ?1,32,93,535 from tax authorities in Goa, adding an incremental liquidity benefit on top of the improved profit trend in Q2 FY26.

While the refund amount of roughly ?1.33 crore is modest relative to the ?1,123 crore profit before tax referenced for the fiscal period, it nevertheless represents a positive cash flow item and removes uncertainty related to the underlying tax claims. For the local entity, having this refund sanctioned reduces administrative overhang and marginally improves free cash flow.

From a group perspective, such regulatory and tax clarifications at the subsidiary level can be constructive, especially in emerging markets, though the primary drivers of Sanofi’s valuation on Nasdaq remain global prescription-drug sales, vaccines, and specialty-care franchises rather than discrete local tax outcomes.

Key vaccine and specialty-care products

Sanofi’s global portfolio includes blockbuster vaccines and specialty-care medicines that underpin its long-term earnings profile. In India, mentions of MenQuadfi in the Scanx Trade coverage point to regulatory progress, with the MenQuadfi meningococcal vaccine recently approved in the European Union for infants from six weeks of age, further broadening its indicated population.

The company’s broader vaccine franchise, alongside treatments in immunology, oncology and rare diseases, continues to shape revenue growth and margin resilience. For US retail investors looking at the Nasdaq-traded ADR, the performance of these global product lines, coupled with regional contributions such as the Q2 FY26 profit uplift in India, helps frame expectations for upcoming quarterly results at the group level.

Sanofi stock and current valuation context

As of the close on August 12, 2026, Sanofi’s ADR price around $43.71 to $43.74 and implied market capitalization of approximately $104.82 billion place the stock within the large-cap pharmaceuticals cohort, where valuation is often benchmarked against peers on metrics such as price-to-earnings and dividend yield.

The slight 0.34% gain in the latest session, followed by a modest 1.05% dip in extended trading, suggests a relatively muted immediate reaction to the incremental positive news from Sanofi India’s Q2 FY26 results and GST refund. However, the 19% year-over-year increase in profit before tax to ?1,123 crore for the fiscal period illustrates that, at least in India, the business is growing faster than low-single-digit industry averages, a factor that could support sentiment if replicated across other key geographies.

For now, Sanofi stock remains anchored by its diversified global portfolio, with the India unit’s ?112 crore profit before tax in Q2 FY26 and the ?1,32,93,535 GST refund providing additional evidence that emerging-market operations are contributing positively to the wider group story.